Lexaria Bioscience licenses DehydraTECH, a technology that improves how active ingredients are absorbed, to drug and consumer product makers. LEXX reports earnings on Wed, Jan 20, 2027.
Earnings
Earnings calendar →Seasonality
How LEXX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in LEXX in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LEXX is in one of them and how their past LEXX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered LEXX in an article yet. Here's the latest on the wider market.
About Lexaria Bioscience
Lexaria Bioscience is a biotechnology company based in Kelowna, British Columbia, Canada. It develops DehydraTECH, a technology that combines active ingredients with certain fatty acid rich oils so the body absorbs them more effectively. The technology can be used in tablets, capsules, oral suspensions, beverages and oral pouches. Lexaria licenses DehydraTECH to drug, nutraceutical and consumer product makers, who build it into their own products.
- Headquarters
- Kelowna, British Columbia, Canada